← Back to Search

Antiplatelet Agent

EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid) for Peripheral Arterial Disease

Phase 4
Waitlist Available
Research Sponsored by LifeBridge Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This trial will test whether adding the drug rivaroxaban to aspirin can help reduce the risk of heart attack and stroke in people who have had a heart attack or stroke in the past.

Eligible Conditions
  • Peripheral Arterial Disease
  • Coronary Artery Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Relative Difference in maximal ADP-induced Platelet Aggregation
Secondary outcome measures
Relative differences in TF-thrombin-induced platelet aggregation
Relative differences in alpha- thrombin-induced platelet aggregation
Relative differences in endogenous thrombin potential
+6 more
Other outcome measures
First occurrence of modified ISTH major bleeding

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)Experimental Treatment2 Interventions
Group II: EC aspirin (81mg qd)Active Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rivaroxaban
FDA approved
Acetylsalicylic acid
FDA approved

Find a Location

Who is running the clinical trial?

Janssen Scientific Affairs, LLCIndustry Sponsor
159 Previous Clinical Trials
580,488 Total Patients Enrolled
3 Trials studying Peripheral Arterial Disease
1,202 Patients Enrolled for Peripheral Arterial Disease
LifeBridge HealthLead Sponsor
28 Previous Clinical Trials
4,338 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy
2020. "Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04059679.
All > Xarelto > Durlaza
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top